argenx SE (ARGX): Price and Financial Metrics

argenx SE (ARGX)

Today's Latest Price: $286.01 USD

1.88 (-0.65%)

Updated Dec 3 2:50pm

Add ARGX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ARGX Stock Summary

  • With a price/sales ratio of 158.77, Argenx Se has a higher such ratio than 97.64% of stocks in our set.
  • Over the past twelve months, ARGX has reported earnings growth of 640.7%, putting it ahead of 97.83% of US stocks in our set.
  • Revenue growth over the past 12 months for Argenx Se comes in at 374.98%, a number that bests 98.1% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Argenx Se are DNLI, ZYME, BNTX, MEIP, and PRQR.
  • Visit ARGX's SEC page to see the company's official filings. To visit the company's web site, go to

ARGX Stock Price Chart Interactive Chart >

Price chart for ARGX

ARGX Price/Volume Stats

Current price $286.01 52-week high $291.23
Prev. close $287.89 52-week low $103.75
Day low $284.74 Volume 171,293
Day high $290.72 Avg. volume 173,888
50-day MA $264.70 Dividend yield N/A
200-day MA $211.74 Market Cap 13.44B

argenx SE (ARGX) Company Bio

arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.

ARGX Latest News Stream

Event/Time News Detail
Loading, please wait...

ARGX Latest Social Stream

Loading social stream, please wait...

View Full ARGX Social Stream

Latest ARGX News From Around the Web

Below are the latest news stories about Argenx Se that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

J&J takeout of Momenta lifts argenx SE

Thinly traded argenx SE (ARGX) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (JNJ) $6.5B takeout of Momenta Pharmaceuticals (MNTA).The Belgian biotech's antibody engineering technology is similar to Momenta's, both involving the Fc region where antibodies modulate other cells in the immune system.In May, argenx reported...

Seeking Alpha | August 19, 2020

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

argenx SE (ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer Conference Call Participants Yaron Werber - Cowen Yatin...

SA Transcripts on Seeking Alpha | August 2, 2020

argenx reports half year 2020 financial results and provides second quarter business update

* Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be presented at upcoming medical meeting in 2020 * Cusatuzumab development strategy aligned with evolving AML treatment landscape to focus on combination with venetoclax and azacitidine * €1.9 billion in cash and cash equivalents and current financial assets strongly support commercial launch preparation of efgartigimod * Management to host conference call today at 2:30 pm CEST (8:30 am ET) July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On argenx SE (ARGX) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 20, 2020

argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | July 1, 2020

Read More 'ARGX' Stories Here

ARGX Price Returns

1-mo 11.09%
3-mo 31.03%
6-mo 26.58%
1-year 89.42%
3-year 832.54%
5-year N/A
YTD 78.18%
2019 67.09%
2018 52.15%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7772 seconds.